COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE ITALIAN SETTING

被引：1
|
作者：
Barbieri, M. [1 ]
Capri, S. [2 ]
Oskar, B. [3 ]
机构：
[1] Univ York, Ctr Hlth Econ, York, N Yorkshire, England
[2] Cattaneo LIUC Univ, Sch Econ & Management, Castellanza, Italy
[3] Celgene Corp, Milan, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.551
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS27
引用
收藏
页码：A419 / A420
页数：2
相关论文
共 50 条
  • [1] COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN SPAIN
    Carrascosa, J. M.
    Vanaclocha, F.
    Caloto, T.
    Echave, M.
    Oyaguez, I
    Tencer, T.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A420 - A420
  • [2] COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN THE ITALIAN SETTING
    Capri, S.
    Barbieri, M.
    Oskar, B.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A646 - A646
  • [3] Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective
    Zargaran, Marzieh
    Soleymani, Fatemeh
    Nasrollahi, Saman Ahmad
    Seyedifar, Meysam
    Rahaghi, Mohammad Mehdi Ashrafian
    [J]. RESEARCH IN PHARMACEUTICAL SCIENCES, 2021, 16 (04) : 381 - 390
  • [4] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Aguirre, A.
    Guerrero, E.
    Hernandez, N.
    Coronell, S.
    Argote, A. C.
    Giraldo, C., V
    Ojeda, C.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A211 - A211
  • [5] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Ojeda, C.
    Hernandez, N.
    Giraldo, C., V
    Argote, A. C.
    Coronell, S.
    Roa, M.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A124 - A124
  • [6] A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
    Colombo, Giorgio L.
    Di Matteo, Sergio
    Peris, Ketty
    Fargnoli, Maria Concetta
    Esposito, Maria
    Mazzotta, Annamaria
    Chimenti, Sergio
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2009, 1 : 53 - 59
  • [7] A COST-UTILITY ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS IN ITALY
    Di Matteo, S.
    Colombo, G. L.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
  • [8] Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis
    Sun, Helen Y.
    Keller, Elena
    Suresh, Harish
    Sebaratnam, Deshan F.
    [J]. JAAD INTERNATIONAL, 2021, 5 : 1 - 8
  • [9] Cost-utility analysis of Amevive™ (alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 331 - 331
  • [10] COST-UTILITY ANALYSIS OF INITIAL TREATMENT WITH APREMILAST VERSUS METHOTREXATE IN SYSTEMIC-NAIVE PATIENTS WITH PLAQUE PSORIASIS
    Higa, S.
    Rueda, J.
    Devine, B.
    [J]. VALUE IN HEALTH, 2018, 21 : S241 - S241
12345